These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 38793711)
1. β-Catenin in Dendritic Cells Negatively Regulates CD8 T Cell Immune Responses through the Immune Checkpoint Molecule Tim-3. Fu C; Wang J; Ma T; Yin C; Zhou L; Clausen BE; Mi QS; Jiang A Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793711 [TBL] [Abstract][Full Text] [Related]
2. GSK-3β in Dendritic Cells Exerts Opposite Functions in Regulating Cross-Priming and Memory CD8 T Cell Responses Independent of β-Catenin. Fu C; Wang J; Ma T; Yin C; Zhou L; Clausen BE; Mi QS; Jiang A Vaccines (Basel); 2024 Sep; 12(9):. PubMed ID: 39340067 [TBL] [Abstract][Full Text] [Related]
3. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells. Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259 [TBL] [Abstract][Full Text] [Related]
4. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Fu C; Liang X; Cui W; Ober-Blöbaum JL; Vazzana J; Shrikant PA; Lee KP; Clausen BE; Mellman I; Jiang A Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2823-8. PubMed ID: 25730849 [TBL] [Abstract][Full Text] [Related]
5. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092 [TBL] [Abstract][Full Text] [Related]
6. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257 [TBL] [Abstract][Full Text] [Related]
7. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491 [TBL] [Abstract][Full Text] [Related]
8. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Aravindaram K; Wang PH; Yin SY; Yang NS Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790 [TBL] [Abstract][Full Text] [Related]
10. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
11. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502 [TBL] [Abstract][Full Text] [Related]
12. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347 [TBL] [Abstract][Full Text] [Related]
14. LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy. Zhang Y; Liu F; Tan L; Li X; Dai Z; Cheng Q; Liu J; Wang Y; Huang L; Wang L; Wang Z J Control Release; 2023 Sep; 361():671-680. PubMed ID: 37591462 [TBL] [Abstract][Full Text] [Related]
17. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751 [TBL] [Abstract][Full Text] [Related]
18. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4 Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774 [No Abstract] [Full Text] [Related]
19. Inhibitory Checkpoint Receptor TIM-3 as a Regulator of the Functional Activity of Dendritic Cells. Tyrinova TV; Chernykh ER Bull Exp Biol Med; 2024 Jul; 177(3):287-292. PubMed ID: 39123087 [TBL] [Abstract][Full Text] [Related]
20. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]